Ujjal Didar Singh Sekhon/LinkedIn
Jul 28, 2026, 08:28
Ujjal Didar Singh Sekhon: Exploring SynthoPlate Under P2Y12 Blockade
Ujjal Didar Singh Sekhon, Director of Research Development at Haima Therapeutics, shared a post on LinkedIn:
“ISTH 2026 was a privilege to be part of: pathbreaking research, illuminating conversations, and a dose of Paris on top.
I was honored to present our work advancing SynthoPlate through models of P2Y12 blockade.
A huge thanks to the Haima team behind this milestone, and to the colleagues who came by with questions and suggestions that will sharpen what comes next.”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM
-
Sep 20, 2026, 00:46Julia R. Coleman: Platelet Biology and Sex Differences in the Plasma Milieu at AAST 2026